



1

---

---

---


---

---

---

---

---



2

---

---

---


---

---

---

---

---



3

---

---

---

---



---

---

---

---

## Nosebleeds



Images by Creative Commons from Microsoft 365

**34** Annual Conferencespn

4

---

---

---

---

---

---

---

---

## Nosebleeds

- 60% lifetime incidence
- 6-10% of patients seek care
- 50% occurrence by age 10 yrs.
- 1 in 10 children report recurrent
- Supportive care management
- 22% worldwide prevalence < 10 yrs. and > 50 yrs.




Image by Creative Commons for Microsoft 365

Passali, D. et al., 2020  
Yan, T. & Goldman, R., 2021

**34** Annual Conferencespn

5

---

---

---

---

---

---

---

---

## Nosebleeds

- Idiopathic
- Trauma
- Inflammation
- Medication
- Structural
- Systemic




Image by Creative Commons for Microsoft 365

Passali, D. et al., 2020  
Sekaly, H., 2021

**34** Annual Conferencespn

6

---

---

---

---

---


---


---

---

### Nosebleeds

- Remain calm
- Have supplies
- Pinch the lower third of the nose
- Pack nose



34<sup>th</sup> Annual Conference 

7

---

---

---

---


---


---

---

---

### What is HHT?



34<sup>th</sup> Annual Conference 

8

---

---

---

---

---

---

---


---

### History of HHT

HEREDITARY EPISTAXIS.  
*To the Editor of THE LANCET.*

- Dr. B Babington, an English physician, first described familial epistaxis in 1865 in a letter to The Lancet editor,
  - 8-year-old boy and his mother

Reynolds, J.R. & Babington, B.G., 1865

34<sup>th</sup> Annual Conference 

9

---

---

---

---


---

---

---


---

## History of HHT



- Dr. Sir William Osler: noted the condition to be a blood vessel disorder versus bleeding disorder, reported characteristic lesions in the GI tract
- Dr. Frederick Weber: published > 1200 articles, series of cases
- Dr. Henri Rendu: observed skin and mucosal findings, differentiated HHT from hemophilia
- Osler-Weber-Rendu (OWR)

CureHHT.org

34<sup>th</sup> Annual Conference


10

---

---

---

---

---

---


---

---

## What is HHT?

- Rare
- 1: 5000
- Autosomal dominant blood vessel disease
- Alterations in TGFβ
- Equal gender expression
- Greater prevalence in Dutch Antilles (Curaçao and Bonaire) 1:1330
- Variable penetrance in the same family

Faughnan, M. et al., 2020

34<sup>th</sup> Annual Conference


11

---

---

---

---

---


---

---


---

## Diagnosing HHT


Autosomal dominant inheritance




HHT



No HHT



50 % chance of HHT for each child

34<sup>th</sup> Annual Conference


12

---

---

---

---

---

---

---

---

## Diagnosing HHT

- Curaçao Criteria
  - 4 criteria
  - If 3 are present, definite diagnosis
  - If 2 are present, possible diagnosis
  - If 1, unlikely diagnosis
- Genetic testing
  - Easier and more affordable than in the past

Shovlin, C., et al., 2000



13

---

---

---

---

---

---

---

---

## Curaçao Criteria

- Epistaxis
  - spontaneous and recurrent
- Telangiectasias in characteristic sites
  - lips, mouth, nose and fingers
  - gastrointestinal tract
- Visceral involvement
  - lungs (pulmonary arteriovenous malformation) PAVM
  - brain (brain arteriovenous malformation) BAVM or spine AVM
  - liver AVM
- First degree relative with HHT diagnosis

Shovlin, C., et al., 2000



14

---

---

---

---

---

---

---

---

## Genetic testing

- Genetic testing
  - Endoglin (HHT1)
  - ACLVR1 (HHT2)
  - SMAD4 (JPS)
  - RASA1
  - GDF2
  - EBPH4



15

---

---

---

---

---

---

---

---

### Nosebleed Phone Inquiries

- We would like to have our son screened because his father had nosebleeds all his life and just found out at age 37 yrs., that he has HHT.
- We were told by grandparents that there is a bleeding problem in the family and there isn't anything we can do about it. Is this true? Everyone has nosebleeds.
- My daughter has terrible nosebleeds and we have seen an ENT physician, and he believes that she may have this disease that I cannot pronounce; He called it HHT. Is this what she has?

16

---

---

---

---

---

---

---

---

### Nosebleeds

- Most common symptom of HHT
- 95% of patients by age 40 yrs.
  - most by age 12 yrs.
- Gush, ooze
- Daily or rarely
- Contribute to anemia
- Families consider symptom normal
- Most bothersome symptom of HHT



Image by Creative Commons for Microsoft365

17

---

---

---

---

---

---

---

---

### Nosebleed Management

- Remain calm
- Have supplies
- Pinch the lower third of nose
- Pack nose
- Moisture
- Trim nails and behavior modification
- Topical therapy
  - Vasoconstrictors (oxymetazoline)
- Anemia



18

---

---

---

---

---

---

---

---

### Epistaxis Severity Screen : ESS

Answer each question about your symptoms as they have occurred over the past three months.

- How often do you TYPICALLY have nose bleeding?
- How long does your TYPICAL nose bleeding last?
- How would you describe your TYPICAL nose bleeding intensity?
- Have you sought medical attention for your nose bleeding?
- Are you anemic (low blood counts) currently?
- Have you received a red blood cell transfusion SPECIFICALLY for nose bleeding?

Hoag, J., 2010



19

---

---

---

---

---

---

---

---

### Nosebleed Management

- Surgical therapy
  - Cautery: laser preferred
  - Embolization: Sotradecol
  - Intralesional injection: Bevacizumab
  - Septal dermoplasty
  - Young's procedure
- Systemic therapy
  - Antibiotic: Doxycycline
  - Antifibrinolytics: Tranexamic acid
  - Antiangiogenic: Bevacizumab, IV and nasal, Pazopanib : oral



20

---

---

---

---

---

---

---

---

### Telangiectasia



- "Red spots"
- Small dilated vessels
- Lips, face, oral cavity, fingers
- GI tract
- Hard to find
- Blanching
- Spider angioma-like



21

---

---

---

---


---

---


---

---

### Telangiectasia



Careful physical examination

34<sup>th</sup> Annual Conference 

22

---

---

---

---

---

---

---

---

### Telangiectasias

Small, 1-4 mm  
Blanch



34<sup>th</sup> Annual Conference 

23

---

---

---

---

---


---

---

---

### Gastrointestinal Complications

- Upper and lower GI bleeding (50+)
- Most common sites are stomach and upper small intestine
- Difficult to treat
- Iron deficiency anemia
- Juvenile Polyposis Syndrome (SMAD4 or HHT3)
  - Endoscopy surveillance for polyp removal
- Liver AVMs
  - Increased prevalence in HHT2
  - Not screened for in children

34<sup>th</sup> Annual Conference 

24

---

---

---

---

---

---

---

---



### Patient case #1

- 8-year-old child seen by ENT for nosebleeds with history of electrocautery x3
- ENT noted a skin telangiectasia on mom
- Mother was diagnosed with ENG mutation.
- 50% of children had mutation
- PAVMs present, nosebleeds



25

---

---

---

---


---

---

---

---

### Arterial venous malformations



CureHHT.org

26

---

---

---

---

---

---

---

---

### Pulmonary Arteriovenous malformations (PAVMs)

- 40-50% of patients will have PAVMs
- 60% of these will have multiple lesions
- PAVMs are rare without HHT
- 90% are simple AVM versus 10% that are complex
- Diffuse PAVMs may occur

27

---

---

---

---

---

---

---

---

### PAVMs

- Asymptomatic
- Cyanotic
- Exercise intolerance (short of breath)
- Hemoptysis
- Hypoxemia
- Migraine headache



34<sup>th</sup> Annual Conference 

28

---

---

---

---

---


---


---

---

### PAVMs

- Still many unknowns
- Might be present at birth
- May develop in childhood
- May develop throughout the lifespan
- Grow slowly



34<sup>th</sup> Annual Conference 

29

---

---

---

---


---


---

---

---

### PAVMs



34<sup>th</sup> Annual Conference 

30

---

---

---

---


---


---

---

---

### PAVM Screening



34<sup>th</sup> Annual Conference 

31

---

---

---

---


---


---

---

---

### Contrast Echocardiogram



34<sup>th</sup> Annual Conference 

32

---

---

---

---

---


---

---


---

### PAVM Management

- Chest CTA after positive bubble echo
- Observation
- Endovascular embolization (2-3 mm)
- Surgical resection
- Antibiotic dental prophylaxis



Faughnan ME, et al., 2020

34<sup>th</sup> Annual Conference 

33

---

---

---

---


---

---


---

---

### PAVM Management



Typical plugs and coils

34<sup>th</sup> Annual Conference 

34

---

---

---

---

---

---

---


---


---

---

### Patient Case #2

- 15-year-old boy in EU after skateboard accident
- SpO2 in the 80's
- Chest x-ray suspicious for PAVMs,
  - Chest CT confirmed PAVMs
- Positive family history of HHT,
  - No previous evaluation



34<sup>th</sup> Annual Conference 

35

---

---

---

---

---

---

---


---


---

---

### PAVMs Complications

- Asymptomatic
- Shortness of breath
- Hypoxia
- Heart failure / Pulmonary hypertension
- Brain abscess
- Stroke
- Death



34<sup>th</sup> Annual Conference 

36

---

---

---

---

---

---

---

---

---

---

## Brain Arteriovenous Malformations (BAVMs)

- Present in 10-20% of patients with HHT
- BAVMs can be singular or multiple
- 1% chance of hemorrhage per BAVM per year
- Spinal AVMs may be present



34<sup>th</sup> Annual Conference

spn

37

---

---

---

---

---


---

---

---

## BAVM Management

- Brain MRI
- MRA with known BAVM
- Sedation
- Management
  - Gamma Knife (stereotactic radiosurgery)
  - Surgical resection
  - Observation



34<sup>th</sup> Annual Conference

spn

38

---

---

---

---

---

---

---

---

## BAVMs Complications

- Intracranial hemorrhage
  - Stroke
  - Seizure
  - Death
- CNS complications
  - Lifelong complications

34<sup>th</sup> Annual Conference

spn

39

---

---

---

---

---

---

---

---

### The Curaçao Criteria and Children

- Pahl, K., et al., 2018
  - 290 patients with a family history of HHT,
  - 4 age groups, 0-5, 6-10, 11-15, and 16-21 years
  - Multicenter chart review
  - Genetic testing, (considered the gold standard) was compared to the Curaçao Criteria
- Conclusions:
  - Curaçao Criteria is reliable to diagnose HHT in children who meet 3-4 criteria. Genetic testing is recommended for patients with 1-2 criteria.
  - Sensitivity lowest in 0-5 and highest in 16-21



40

---

---

---

---

---


---

---

---

### HHT Referral

- CureHHT Centers of Excellence (CoE)
- Proactively manage the care of patients with HHT
- Review and plan with HHT specialist
- Multidisciplinary team of experts
- HHT specialists work closely with an HHT coordinator
- Subspecialties include cardiology, neurology, neurosurgery, radiology, hematology and others



41

---

---

---

---

---

---

---

---

### HHT Referral

- Comprehensive phone intake by coordinator
- Obtain and review records
- Family and facility confirm insurance
- Plan evaluation with CoE or specialist



42

---

---

---

---

---

---

---

---

### International Pediatric Guidelines

The expert panel recommends....	Quality of Evidence (Agreement %)	Strength of Recommendation (Agreement %)
E1: that diagnostic genetic testing be offered for asymptomatic children of a parent with HHT.	High (96%)	Strong (94%)
E2: screening for pulmonary AVMs in asymptomatic children with HHT or at risk for HHT at the time of presentation / diagnosis.	Moderate (94%)	Strong (94%)
E3: that large pulmonary AVMs and pulmonary AVMs associated with reduced oxygen saturation be treated in children to avoid serious complications.	Moderate (98%)	Strong (98%)
E4: repeating pulmonary AVM screening in asymptomatic children with HHT or at risk for HHT; typically at 5 year intervals.	Low (92%)	Strong (86%)
E5: screening for brain VM in asymptomatic children with HHT, or at risk for HHT, at the time of presentation / diagnosis.	Low (86%)	Strong (86%)
E6: that brain VMs with high risk features be treated.	Low (100%)	Strong (98%)

Faughnan ME, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020 Dec;173(12):989-1001. PMID: 32894995



43

---

---

---

---

---

---


---

---

---

---

### HHT Screening



44

---

---

---

---

---

---

---


---

---

---

### HHT Consultation

- History and physical examination
- Pulse oximetry
- Bubble echocardiogram
- Brain MRI
- Genetic testing
- Other specialty appointments as needed
- Review of all tests, plans at the end of the day



45

---

---

---

---

---

---

---

---

---

---

### HHT Follow up

- Education and guidance
- Individualized appointment follow up
  - Months-5 years
  - PRN
- No scuba diving
- Limit NSAID use, avoid Aspirin
- Visit HHT CoE at least once



46

---

---

---

---

---

---

---

---

---

---

### Patient Case #2

- Summary of HHT center consultation:
  - SpO2 88% on room air at presentation
  - Nosebleeds, telangiectasias, clubbing of nailbeds
  - Positive genetic marker in ENG (HHT1)
  - Embolization of 3 PAVMs, feeding vessel was 5 mms

47

---

---

---

---

---

---

---

---

---

---

### Patient Case #3

- 4-year-old asymptomatic boy presents to HHT center for evaluation, Dad with ENG mutation
- Patient tests positive for ENG
- Brain MRI reveals right parietal occipital AVM (12mm)
- Craniotomy for removal of AVM
- Positive bubble echocardiogram



48

---

---

---

---

---

---

---

---

---

---



### Delay in Diagnosis

- Underdiagnosed
- Long diagnostic delay
- Pierucci, P. et al., 2012
  - 233 participants, 88 patients received Dx at first visit
  - Clinical signs at age 14 yrs., referral at age 29
  - Dx at 40 yrs. with lag time of 25.7 yrs.
  - 22 pts suffered severe complications during interval

49

---

---

---

---

---

---

---

---

### Case presentation

- 5-year-old boy found unconscious at his home
  - EMS arrived within 10 minutes
  - Transferred to hospital
  - Family history of HHT
  - Asymptomatic
  - Never evaluated

50

---

---

---

---

---

---

---

---

### Living with HHT

- No Cure
- Uncertainty
- Denial
- Family support
- Advocacy
- Research

Palmer, S. 2017

51

---

---

---

---

---


---


---

---

Thank you!

HHT patients and families  
Dr. Andrew J. White  
Dr. Katherine Amba  
Curehht.org  
HHT providers  
Researchers  
SPN



34<sup>th</sup> Annual Conference 

---

---

---

---

---

---

---

---